GM Advisory Group LLC Acquires 552 Shares of Eli Lilly and Company $LLY

Key Points

• GM Advisory Group LLC has increased its stake in Eli Lilly and Company by 4.8%, accumulating nearly 12,000 shares valued at approximately $9.86 million.
• Eli Lilly recently reported earnings of $6.31 per share, surpassing analysts' expectations by $0.72, with revenue increasing 37.6% year-over-year to $15.56 billion.
• The company declared a quarterly dividend of $1.50 per share, which translates to an annualized yield of 0.9%, with a payout ratio of 39.22%.

GM Advisory Group LLC lifted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,938 shares of the company's stock after buying an additional 552 shares during the period. GM Advisory Group LLC's holdings in Eli Lilly and Company were worth $9,859,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in LLY. Knightsbridge Asset Management LLC increased its position in shares of Eli Lilly and Company by 1.9% during the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock valued at $628,000 after purchasing an additional 15 shares during the period. Corient IA LLC acquired a new stake in Eli Lilly and Company during the first quarter worth $570,000. LS Investment Advisors LLC increased its holdings in Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock valued at $1,933,000 after buying an additional 40 shares during the period. Prism Advisors Inc. bought a new stake in Eli Lilly and Company in the 1st quarter valued at $207,000. Finally, CSM Advisors LLC raised its stake in shares of Eli Lilly and Company by 30.6% in the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock valued at $807,000 after buying an additional 245 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on LLY. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday. Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Finally, Guggenheim lowered their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $950.17.

Insiders Place Their Bets

In other news, Director Jamere Jackson acquired 200 shares of the firm's stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last quarter. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $3.3830 during midday trading on Thursday, reaching $708.8230. The company's stock had a trading volume of 3,611,878 shares, compared to its average volume of 6,931,770. The business's fifty day simple moving average is $756.85 and its 200-day simple moving average is $791.70. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $972.53. The company has a market capitalization of $670.87 billion, a P/E ratio of 46.33, a P/E/G ratio of 0.98 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.